Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 301

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 301
---
 in 2024. The increase in research and development expenses was primarily driven by higher costs associated with our Shingles program due to the ongoing Phase 1/2 clinical trial, increased investment in the initiation and completion of enrollment for Part 1 of a Phase 1/2 clinical study for our pandemic influenza program, and continued work on IND-enabling activities for our Lyme disease program, which 

32

began in the first quarter of 2025. These increases were partially offset by reduced expenses following the discontinuation of our Tdap program in late 2024.

As we continue to progress our clinical and preclinical stage pipeline, we expect research and development expenses to continue to represent a substantial portion of our expenses and to continue to increase, both in dollar amount and proportion of total expense, in future years.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of compensation and related costs for our commercial support personnel, medical education professionals, and personnel in executive and other administrative functions, including legal, finance and information technology; costs for outside services such as sales and marketing, post-marketing studies of HEPLISAV-B, accounting, commercial development, consulting, business development, investor relations and insurance; legal costs that include corporate and patent-related expenses; allocated facility costs and non-cash stock-based compensation.

The following is a summary of our selling, general and administrative expenses (in thousands, except for percentages): 

Selling, General and Administrative:Three Months EndedJune 30,Increase (Decrease) from 2024 to 2025Six Months EndedJune 30,Increase (Decrease) from 2024 to 202520252024$%20252024$%Compensation and related personnel costs$17,182 $18,018 $(836)(5%)$35,100 $36,677 $(1,577)(4%)Outside services22,307 12,622 9,685 77%38,799 26,101 12,698 49%Facility costs2,047 1,767 280 16%5,366 4,774 592 12%Non-cash stock-based compensation8,823 9,255 (432)(5%)18,772 18,175 597 3%Total selling, general and administrative$50,359 $41,662 $8,697 21%$98,037 $85,727 $12,310